tiprankstipranks
Trending News
More News >
Humana AB (SE:HUM)
:HUM

Humana AB (HUM) AI Stock Analysis

Compare
5 Followers

Top Page

SE:HUM

Humana AB

(HUM)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 5.2)
Rating:52Neutral
Price Target:
kr49.00
▼(-2.78% Downside)
Action:DowngradedDate:02/08/26
The score is anchored by middling financial performance: weakening revenue/margins and higher leverage offset stable operations and generally decent cash conversion. Technicals are a meaningful drag due to a clear downtrend and negative momentum, while the low P/E and dividend yield provide a notable valuation cushion.
Positive Factors
Publicly funded recurring revenue model
Revenue tied to public reimbursements and contracted care creates a durable, recurring cash flow base. This reduces cyclical demand sensitivity and supports predictable billing and utilization over multi-year procurement cycles, underpinning steady revenue even in macro slowdowns.
Scale and specialization in Nordic social care
Operating scale across multiple care segments in the Nordic public system gives Humana operational expertise and procurement leverage. Specialized service mix (personal assistance, youth, residential) increases stickiness with public clients and enables cross-selling within municipal contracts.
Generally solid cash generation and FCF conversion
Historically strong cash conversion that covered profits supports reinvestment capacity and earnings quality. Even with 2025 softening, consistent FCF linkage to net income indicates the business generates operating cash to fund working capital and service obligations over the medium term.
Negative Factors
Top-line weakness and declining revenue trend
A shift from modest growth to a 2025 revenue decline suggests structural pressure on demand, reimbursement levels, or contract wins. Sustained top-line weakness erodes scale economics, limits margin recovery, and reduces bargaining power with public purchasers over the next several quarters.
Rising leverage and elevated debt load
A materially higher debt burden tilts the capital structure toward liability risk. Elevated leverage reduces financial flexibility to invest or absorb reimbursement shocks, increases refinancing risk, and constrains ability to pursue roll-up or service expansion without worsening covenants.
Margin compression and thin net profitability
Sharp gross-margin compression combined with thin, volatile net margins leaves earnings sensitive to staffing costs and reimbursement changes. Limited margin cushion reduces capacity to absorb cost inflation and undermines sustainable free cash flow if revenue trends don't reverse.

Humana AB (HUM) vs. iShares MSCI Sweden ETF (EWD)

Humana AB Business Overview & Revenue Model

Company DescriptionHumana AB (publ) provides individual and family care services for children and adults in Sweden, Finland, Norway, and Denmark. It operates through five segments: Individual & Family, Personal Assistance, Elderly Care, Finland, and Norway segments. The Individual & Family segment provides care and treatment for psychosocial disorders, mental illness, and functional impairment; residential care homes; interim and regular family-based care services; special service housing; outpatient care services; assisted living homes; and specially adapted housing for individuals with functional impairments and special education schools. The Personal Assistance segment offers care services and assistance to individuals with functional impairments. The Elderly Care segment provides elderly care home services. The Finland segment offers individual and family care for children, young people and families with psychiatric diagnoses or psychosocial disorders; special service housing for individuals with functional impairments; elderly care homes; and elderly day care services. The Norway segment provides individual and family care, personal assistance, and special service housing for individuals with functional impairments. The company was founded in 2001 and is headquartered in Stockholm, Sweden.
How the Company Makes MoneyHumana AB primarily makes money by providing publicly funded social-care services and being reimbursed for delivering those services. Its key revenue streams typically include: (1) Personal assistance services, where Humana provides caregivers and administrative coordination for eligible individuals and earns revenue through reimbursement tied to approved assistance hours and applicable compensation rates set by public authorities; (2) Residential and support services (e.g., care homes, supported living, and other placement-based offerings), where municipalities or other public purchasers pay fees for placements, occupancy, and ongoing care provision; and (3) Specialist/individualized care services for children, youth, families, and adults with specific care needs, where revenue is generated via contracted service delivery, referrals, and placement agreements with public entities. Significant factors influencing earnings generally include the volume of approved care hours or placements, occupancy/utilization in residential operations, reimbursement and pricing levels determined by government frameworks, staffing costs and the ability to recruit/retain qualified personnel, quality/compliance outcomes that affect eligibility to operate under public procurement and regulatory oversight, and the mix between different service types. Specific details on material commercial partnerships and the exact breakdown of revenue by segment are null.

Humana AB Financial Statement Overview

Summary
Fundamentals are stable but constrained: revenue momentum weakened into a 2025 decline and gross margin compressed sharply, while net margin remains thin. Cash conversion is generally decent but softened in 2025, and the balance sheet is a key risk with meaningfully higher debt and elevated leverage versus equity.
Income Statement
52
Neutral
Revenue growth has slowed materially, with 2025 showing a decline after modest expansion in 2023–2024. Profitability is mixed: operating profitability is relatively steady, but gross margin compressed sharply in 2025 versus prior years, and net margin remains thin and somewhat volatile (notably improving in 2025 versus 2024, but still low). Overall, the income statement reflects stable operations with weakening top-line momentum and pressure on underlying margins.
Balance Sheet
45
Neutral
Leverage is a key constraint: debt has risen meaningfully in 2025 and the debt load remains high versus equity, with debt-to-equity increasing to above prior-year levels. Returns on equity are positive but not consistently improving and remain moderate, suggesting the balance sheet is working but with limited cushion if operating conditions weaken. Asset base is sizable, but the capital structure is tilted toward debt, raising financial risk.
Cash Flow
58
Neutral
Cash generation is generally solid and supports earnings quality: free cash flow tracks net income well across the period (and in 2024 it fully covered reported profit). That said, 2025 free cash flow declined and operating cash flow coverage remains modest, indicating the company does not have a large cash-flow buffer relative to its obligations. Overall cash flow is steady, but recent momentum has softened.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue10.01B10.29B9.65B9.20B8.19B
Gross Profit427.00M896.00M757.00M9.14B8.13B
EBITDA1.11B1.05B908.00M901.00M892.00M
Net Income237.00M144.00M176.00M210.00M276.00M
Balance Sheet
Total Assets9.39B10.63B10.03B9.81B9.00B
Cash, Cash Equivalents and Short-Term Investments366.00M583.00M675.00M690.00M695.00M
Total Debt6.72B5.15B5.41B5.40B4.92B
Total Liabilities6.14B7.33B7.10B7.07B6.45B
Stockholders Equity3.12B3.16B2.89B2.74B2.55B
Cash Flow
Free Cash Flow666.00M570.00M451.00M442.00M582.00M
Operating Cash Flow770.00M869.00M621.00M633.00M689.00M
Investing Cash Flow172.00M-532.00M-151.00M-246.00M-260.00M
Financing Cash Flow-1.13B-434.00M-457.00M-424.00M-521.00M

Humana AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price50.40
Price Trends
50DMA
46.68
Negative
100DMA
46.95
Negative
200DMA
42.92
Positive
Market Momentum
MACD
0.25
Negative
RSI
49.75
Neutral
STOCH
44.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HUM, the sentiment is Negative. The current price of 50.4 is above the 20-day moving average (MA) of 44.81, above the 50-day MA of 46.68, and above the 200-day MA of 42.92, indicating a neutral trend. The MACD of 0.25 indicates Negative momentum. The RSI at 49.75 is Neutral, neither overbought nor oversold. The STOCH value of 44.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:HUM.

Humana AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
kr15.25B11.621.47%2.96%73.50%
64
Neutral
kr1.74B31.6213.36%-20.56%
63
Neutral
kr10.64B17.7812.96%1.56%10.83%16.24%
54
Neutral
kr1.60B54.90
52
Neutral
kr2.36B10.627.53%2.01%2.11%92.69%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
43
Neutral
kr1.03B-7.05-35.03%25.14%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:HUM
Humana AB
45.55
0.64
1.43%
SE:ATT
Attendo AB
99.80
39.38
65.17%
SE:AMBEA
Ambea AB
134.10
25.55
23.54%
SE:XSPRAY
Xspray Pharma AB
24.70
-4.72
-16.03%
SE:STIL
Stille AB
194.00
-53.00
-21.46%
SE:CARA
Carasent AB
23.35
1.04
4.64%

Humana AB Corporate Events

Humana to Double LSS Daily Activity Services with Homsan Acquisition
Mar 10, 2026

Humana has agreed to acquire Homsan AB, a Stockholm-region provider of daily activities under LSS, more than doubling Humana’s daily activity services and significantly expanding its local footprint. Homsan runs 13 units with around 200 participants and SEK 63 million in annual sales, mainly under LOV agreements with Stockholm city and Huddinge municipality.

The deal, financed with existing cash and expected to close in April 2026, will increase Humana’s daily activity participants from about 160 to 360 and deepen its specialist offering for people with extensive needs. The acquisition aligns with Humana’s strategy to grow in high-need social care segments where quality, structure and long-term operations are key, strengthening its competitive position in the Stockholm market.

The most recent analyst rating on (SE:HUM) stock is a Hold with a SEK44.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana Boosts Profitability, Cuts Debt and Lifts Dividend Despite Lower 2025 Revenue
Feb 6, 2026

Humana AB reported weaker fourth-quarter 2025 revenue of SEK 2,483 million, down 8% year-on-year, with organic growth at -1.9% and adjusted operating profit falling to SEK 87 million, while full-year net revenue slipped 3% but operating profit rose 9% and net profit surged to SEK 238 million, helped by stronger margins over the year and lower leverage, as net debt excluding leases dropped 20% to SEK 1,199 million. Despite lower sales volumes, fewer customers and a reduced workforce, the care group strengthened cash generation with a higher fourth-quarter free cash flow of SEK 174 million, increased its client satisfaction index to 85, completed the acquisition of Norway’s Familiehjelpgruppen, secured an agreement for a new elderly care home in Sollentuna, achieved SBTi validation of its climate targets, and proposed a 35% higher dividend of SEK 1.35 per share for the 2025 financial year, underscoring management’s confidence in future growth driven by a stronger project pipeline and bolt-on acquisitions.

The most recent analyst rating on (SE:HUM) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana AB Launches Share Buyback to Bolster Capital Structure and Acquisition Flexibility
Feb 6, 2026

Humana AB’s board has decided to repurchase up to 1,000,000 of the company’s own shares under a mandate from the 2025 annual general meeting, aiming to strengthen its capital structure and increase strategic flexibility for potential future acquisitions. The buybacks, to be executed in cash via an investment firm on Nasdaq Stockholm in line with the Nordic Main Market Rulebook, will be completed before the 2026 annual general meeting and are limited so that Humana’s total holding of treasury shares does not exceed 10% of its 51,826,058 outstanding shares, adding to the 3,485,273 shares the company already holds and signalling an active approach to capital management that may support shareholder value and acquisition-driven growth.

The most recent analyst rating on (SE:HUM) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana Completes Acquisition of Norwegian Care Provider Familiehjelpgruppen
Feb 2, 2026

Humana AB has completed the acquisition of Norwegian care provider Familiehjelpgruppen AS, following approval from the national Competition Authority. The deal significantly expands Humana’s preventive care and support services for children and young people in Norway, particularly within foster homes, and strengthens its position as a leading care provider in this segment. Familiehjelpgruppen, which generates annual revenues of about NOK 120 million, will be consolidated into Humana’s accounts from 2 February 2026, adding both service breadth and specialist staff to Humana’s Norwegian operations.

The most recent analyst rating on (SE:HUM) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana to Present Fourth-Quarter and Full-Year 2025 Results on 6 February
Jan 27, 2026

Humana AB has announced that it will publish its interim report for the fourth quarter and full year 2025 on 6 February 2025 at 08:00 CET, followed by a webcast and telephone conference at 09:00 CET where CEO and President Nathalie Boulas Nilsson and CFO Christoffer Herou will present the results. The report presentation, including slides and both live and recorded webcasts, will be made available via Humana’s and Financial Hearings’ websites, offering investors and other stakeholders multiple channels for participation and Q&A, underlining the company’s commitment to transparent financial communication and engagement with the capital market.

The most recent analyst rating on (SE:HUM) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana Expands Elderly and LSS Care with New Central Sollentuna Facility
Jan 23, 2026

Humana has signed an agreement with property owner Knut Olsson Fastigheter AB to establish a new modern elderly care home with 100 beds and an LSS group home with six beds in central Sollentuna, just beside the municipal council hall and major public transport links. Scheduled for completion in 2028 and to be run by Humana within Sollentuna’s Freedom of Choice System, the environmentally certified facility supports both companies’ long-term strategies—accelerating Humana’s growth in elderly care, one of its prioritized expansion areas, while advancing Knut Olsson Fastigheter’s focus on sustainable, socially oriented properties—and aligns with the municipality’s ambition to broaden high-quality care options and enhance living conditions for older people and individuals with disabilities.

The most recent analyst rating on (SE:HUM) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana’s Nomination Committee Backs Full Board Re-Election and Continued Chairmanship
Jan 13, 2026

Humana’s Nomination Committee is proposing that the company’s Board of Directors for the 2026 financial year remains at seven members elected by the AGM, with all current directors – Grethe Aasved, Carolina Oscarius Dahl, Monica Lingegård, Leena Munter, Anders Nyberg, Ralph Riber and Fredrik Strömholm – standing for re-election and Nyberg put forward to continue as Chairman. The committee, composed of representatives from major shareholders and the current chair, stresses the importance of continuity after the addition of several new directors in 2023 and amid recent changes in senior management, signalling a clear preference for stability in governance as Humana navigates its ongoing development in key operational areas ahead of the AGM on 7 May 2026.

The most recent analyst rating on (SE:HUM) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana AB Expands Preventive Care Services with Acquisition of Familiehjelpgruppen AS
Dec 12, 2025

Humana AB has announced the acquisition of Familiehjelpgruppen AS, a respected provider of family-based care services in Norway. This acquisition will enhance Humana’s capacity in foster homes and expand its offerings in preventive care, particularly for children and young people. The transaction, expected to complete in January 2026, will be financed with existing cash and is subject to regulatory approval. This strategic move is set to strengthen Humana’s market position and service quality, aligning with its focus on quality, ethics, and the best interests of children.

The most recent analyst rating on (SE:HUM) stock is a Buy with a SEK52.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 08, 2026